Basic Study
Copyright ©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Mar 24, 2025; 16(3): 94091
Published online Mar 24, 2025. doi: 10.5306/wjco.v16.i3.94091
Transmembrane channel-like 5 drives hepatocellular carcinoma progression by regulating epithelial-mesenchymal transition
Jiao Li, Zi-Yu Wang, Yan Jin, Jing Xu, Yun-Jin Ya, Ting-Qiu Wan, Xi Li, Xi Wang
Jiao Li, Zi-Yu Wang, Yan Jin, Jing Xu, Yun-Jin Ya, Ting-Qiu Wan, Xi Li, Xi Wang, Department of Hepatobiliary Surgery, The Affiliated Hospital of Kunming University of Science and Technology, Kunming 650500, Yunnan Province, China
Co-first authors: Jiao Li and Zi-Yu Wang.
Co-corresponding authors: Yan Jin and Jing Xu.
Author contributions: Li J and Wang ZY contribute equally to this study as co-first authors; Jin Y and Xu J contribute equally to this study as co-corresponding authors; Li J, Wang ZY, Xu J, and Jin Y conceived and designed the experiments; Li J, Wang ZY, Ya YJ, Wan TQ, Li X, and Wang X performed the experiments; Li J and Wang ZY analyzed the data; Xu J and Jin Y contributed to data curation; Li J and Wang ZY contributed to original draft; Ya YJ, Wan TQ, Li X, Wang X, Xu J, and Jin Y contributed to review and edit.
Supported by the Yunnan Provincial Department of Science and Technology-Kunming Medical University Joint Special Project on Applied Basic Research, No. 202401AY070001-132; the Yunnan Provincial Science Foundation, No. 2018FE001(-287), National Natural Science Foundation of China, No. 81460443; and the Ten Thousand People Plan of Yunnan Province, No. KH-SWR-MY-2020-002.
Institutional review board statement: The study was approved by the Affiliated Hospital of Kunming University of Science and Technology.
Institutional animal care and use committee statement: The study was approved by the Ethics Committee of the Affiliated Hospital of Kunming University of Science and Technology.
Conflict-of-interest statement: The authors declare that there is no conflict of interest.
Data sharing statement: The datasets analyzed during the current study are available from the corresponding author upon reasonable request.
ARRIVE guidelines statement: The authors have read the ARRIVE guidelines, and the manuscript was prepared and revised according to the ARRIVE guidelines.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Yan Jin, Chief Physician, Department of Hepatobiliary Surgery, The Affiliated Hospital of Kunming University of Science and Technology, No. 157 Jinbi Road, Xishan District, Kunming 650500, Yunnan Province, China. 13312503258@163.com
Received: March 11, 2024
Revised: October 17, 2024
Accepted: November 25, 2024
Published online: March 24, 2025
Processing time: 315 Days and 23.4 Hours
Core Tip

Core Tip: In this study, transmembrane channel-like 5 (TMC5), which is highly expressed in hepatocellular carcinoma (HCC) and associated with increased invasive migration ability, is proposed for the first time as a potential marker for HCC. Bioinformatics analysis and in vivo and in vitro experiments confirmed that TMC5 regulates epithelial-mesenchymal transition to promote invasive migration in HCC. TMC5 might be a valuable molecular target for HCC diagnosis and treatment.